Skip to content
Rifamycin
Aemcolo (rifamycin) is a small molecule pharmaceutical. Rifamycin was first approved as Aemcolo on 2018-11-16. It is known to target solute carrier organic anion transporter family member 1A2, solute carrier organic anion transporter family member 2B1, solute carrier organic anion transporter family member 1B1, and solute carrier organic anion transporter family member 1B3.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Aemcolo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rifamycin sodium
Tradename
Company
Number
Date
Products
AEMCOLORedHill BiopharmaN-210910 RX2018-11-16
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
aemcoloNew Drug Application2021-07-01
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
RIFAMYCIN SODIUM, AEMCOLO, REDHILL
2028-11-16GAIN
2023-11-16NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Rifamycin Sodium, Aemcolo, Redhill
82631202025-05-03DP
84864462025-05-03DP
85299452025-05-03DP
87419482025-05-03DPU-2448
ATC Codes
A: Alimentary tract and metabolism drugs
A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
A07A: Intestinal antiinfectives
A07AA: Antibiotics, intestinal
A07AA13: Rifamycin
D: Dermatologicals
D06: Antibiotics and chemotherapeutics for dermatological use
D06A: Antibiotics for topical use
D06AX: Other antibiotics for topical use in atc
D06AX15: Rifamycin
J: Antiinfectives for systemic use
J04: Antimycobacterials
J04A: Drugs for treatment of tuberculosis
J04AB: Antibiotics, antitubercular
J04AB03: Rifamycin
S: Sensory organ drugs
S01: Ophthalmologicals
S01A: Antiinfective ophthalmologics
S01AA: Antibiotics, ophthalmologic
S01AA16: Rifamycin
S02: Otologicals
S02A: Antiinfective drugs, otologic
S02AA: Antiinfectives
S02AA12: Rifamycin
HCPCS
No data
Clinical
Clinical Trials
118 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
KeratoconusD007640EFO_0004223H18.68162331051
Hiv infectionsD015658EFO_0000764B20123
Lactic acidosisD000140EFO_1000036E87.201112
Surgical amputationD00067111
OsteomyelitisD010019EFO_0003102M8611
FatigueD005221HP_0012378R53.8311
Acquired immunodeficiency syndromeD000163EFO_0000765B2011
LipodystrophyD008060E88.111
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pathologic dilatationD0041084439
KeratitisD007634H16233
Crohn diseaseD003424EFO_0000384K50112
InfectionsD007239EFO_0000544112
Mycobacterium tuberculosisD00916911
Closed head injuriesD01648911
Oral ulcerD019226HP_000015511
Corneal neovascularizationD016510EFO_1000880H16.4111
Diabetic neuropathiesD003929EFO_100078311
Hematologic diseasesD006402EFO_0005803D75.911
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple sclerosisD009103EFO_0003885G35112
Chronic painD059350HP_001253211
ComplianceD00318711
Pancreatic neoplasmsD010190EFO_0003860C2511
Gastrointestinal microbiomeD00006919611
DeliriumD003693R41.011
Delayed emergence from anesthesiaD05519111
Neurocognitive disordersD019965F0911
Myocardial infarctionD009203EFO_0000612I2111
PsoriasisD011565EFO_0000676L4011
Show 13 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Carpal tunnel syndromeD002349EFO_0004143G56.011
Burning mouth syndromeD002054EFO_100085011
Corneal ulcerD003320H16.011
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Blood pressureD001794EFO_000432533
Healthy volunteers/patients22
HypertensionD006973EFO_0000537I1022
PregnancyD011247EFO_0002950Z33.111
Pelvic floor disordersD05995211
Migraine disordersD008881EFO_0003821G4311
Medication adherenceD055118EFO_000634411
Ehlers-danlos syndromeD004535Orphanet_98249Q79.611
GlaucomaD005901EFO_0000516H4011
AnemiaD000740EFO_0004272D64.911
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRIFAMYCIN
INNrifamide
Description
Rifamycin SV is a member of the class of rifamycins that exhibits antibiotic and antitubercular properties. It has a role as a bacterial metabolite, an antimicrobial agent and an antitubercular agent. It is a member of rifamycins, an acetate ester, a cyclic ketal, a lactam, a macrocycle, a polyphenol and an organic heterotetracyclic compound. It is a conjugate acid of a rifamycin SV(1-).
Classification
Small molecule
Drug classantibiotics (Streptomyces strain); antibiotics (rifamycin derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(cc(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
Identifiers
PDB
CAS-ID6998-60-3
RxCUI
ChEMBL IDCHEMBL437765
ChEBI ID29673
PubChem CID6324616
DrugBankDB11753
UNII IDTS121H7U7E (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
SLCO1A2
SLCO1A2
SLCO2B1
SLCO2B1
SLCO1B1
SLCO1B1
SLCO1B3
SLCO1B3
Organism
Homo sapiens
Gene name
SLCO1A2
Gene synonyms
OATP, OATP1, OATP1A2, SLC21A3
NCBI Gene ID
Protein name
solute carrier organic anion transporter family member 1A2
Protein synonyms
OATP-1, OATP-A, organic anion transporting polypeptide A, Organic anion-transporting polypeptide 1, Sodium-independent organic anion transporter, solute carrier family 21 (organic anion transporter), member 3, Solute carrier family 21 member 3
Uniprot ID
Mouse ortholog
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 5,335 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,416 adverse events reported
View more details